cagrisema phase 3 results 2025 cagrilintide semaglutide combination obesity drug: what the data shows cagrisema phase 3 results 2025
cagrisema phase 3 results 2025 semaglutide cagrilintide obesity We are all anxiously awaiting more research on Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine
Pay in 4 interest-free payments of $5.91 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8

